Prostate Cancer: An Update on Disease Pathogenesis and Drug Therapy- Pharmacist


  Credits  2

This product is currently out of stock and unavailable.

Over the last decade, much progress has been made in both the diagnosis and treatment of prostate cancer. One contributing factor is prostate-specific antigen (PSA) screening, which began in the 1980s. Widespread screening is controversial; however, because many early-stage cancers are slow-growing and treatment may result in more harm than benefit. Conversely, the curative treatments for early disease (i.e., surgery and radiation) offer improved success rates. Treatment options for advanced disease are also better - hormonal therapy is commonly started earlier in the course of the disease, and chemotherapeutic regimens have improved. Despite positive trends, prostate cancer remains the most common non-skin cancer in men, and the second most lethal tumor among men. About 1 in 6 men will be diagnosed with prostate cancer, but only 1 in 35 men will die of it. This issue provides an overview of prostate cancer including risk factors, screening recommendations, symptoms, and diagnosis. Recommended treatment options to consider for early as well as more advanced cancer are discussed. A drug review focuses on the hormonal therapies (luteinizing hormone-releasing hormone [LHRH] agonists and antiandrogens) that are typically used for both localized prostate cancer and more advanced cancer. Strategies to manage common and serious adverse effects of these treatments are provided. Finally the Patient Connection offers answers to questions that patients often have about prostate cancer and hormonal therapies.


Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 428-0000-09-001-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.